GeneFormatics Overview
- Year Founded
-
1998
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
GeneFormatics General Information
Description
Developer of novel function prediction methods. The company's products is used for the rapid identification of biologically relevant targets from the vast amounts of sequence data produced by the world-wide genomics projects.
Contact Information
Website
www.geneformatics.comCorporate Office
- 5830 Oberlin Drive
- Suite 200
- San Diego, CA 92121
- United States
Corporate Office
- 5830 Oberlin Drive
- Suite 200
- San Diego, CA 92121
- United States
GeneFormatics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 19-May-2003 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series C) | 06-Dec-2002 | Completed | Generating Revenue | |||
| 3. Early Stage VC | 01-Oct-2001 | Completed | Product Development | |||
| 2. Early Stage VC (Series B) | 06-Oct-2000 | $15M | $19M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 01-Feb-2000 | $4M | $4M | Completed | Product Development |
GeneFormatics Patents
GeneFormatics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2002319620-A1 | Functional site profiles for proteins and methods of making and using the same | Inactive | 21-Jul-2001 | ||
| WO-2003010285-A2 | Functional site profiles for proteins and methods of making and using the same | Inactive | 21-Jul-2001 | ||
| WO-2003010285-A3 | Functional site profiles for proteins and methods of making and using the same | Inactive | 21-Jul-2001 | ||
| US-20030096307-A1 | Generation of activity and physical profile of protein; obtain protein model, define active site, indentify amino acids in active site | Inactive | 21-Jul-2001 | ||
| AU-2001294822-A1 | Methods for determining aproximations of three dimensional polypeptide structure | Inactive | 26-Sep-2000 | G16B30/00 |
GeneFormatics Former Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Aisling Capital | Venture Capital | Minority | ||
| Bruker | Corporation | Minority | ||
| Burrill & Co | Merchant Banking Firm | Minority | ||
| CDIB Capital Group | Asset Manager | Minority | ||
| GeneChem | Venture Capital | Minority |
GeneFormatics FAQs
-
When was GeneFormatics founded?
GeneFormatics was founded in 1998.
-
Where is GeneFormatics headquartered?
GeneFormatics is headquartered in San Diego, CA.
-
What industry is GeneFormatics in?
GeneFormatics’s primary industry is Biotechnology.
-
Is GeneFormatics a private or public company?
GeneFormatics is a Private company.
-
What is GeneFormatics’s current revenue?
The current revenue for GeneFormatics is .
-
How much funding has GeneFormatics raised over time?
GeneFormatics has raised $66.8M.
-
Who are GeneFormatics’s investors?
Aisling Capital, Bruker, Burrill & Co, CDIB Capital Group, and GeneChem are 5 of 11 investors who have invested in GeneFormatics.
-
When was GeneFormatics acquired?
GeneFormatics was acquired on 19-May-2003.
-
Who acquired GeneFormatics?
GeneFormatics was acquired by Cengent Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
